Practical Fragments

This blog is meant to allow Fragment-based Drug Design Practitioners to get together and discuss NON-CONFIDENTIAL issues regarding fragments.

Showing posts with label Novartis. Show all posts
Showing posts with label Novartis. Show all posts
12 January 2015

Choosing fragments and assays

›
One of the advantages of running lots of fragment screens is that it generates lots of data that you can mine for general trends and insigh...
29 September 2014

FBLD 2014

›
FBLD 2014 , the fifth in an illustrious series of conferences, took place in Basel, Switzerland last week. Organizers Wolfgang Jahnke ( No...
4 comments:
29 April 2013

Fragment merging for renin

›
Renin, an aspartic protease involved in regulating blood pressure, is one of those drug targets that has been around forever; it took decade...
20 September 2010

Allosteric FPPS inhibitors – not so negative

›
The protein farnesyl pyrophosphate synthase (FPPS) has long been a target of drugs for osteoporosis, and some data have suggested it could b...
31 May 2010

Fragments vs Abl: antagonists and agonists

›
A common concern with using biophysical techniques to identify fragments is that the functional implications of identified binders are not a...
26 March 2010

ACS Spring Meeting 2010

›
The spring national meeting of the American Chemical Society has just concluded in (uncharacteristically sunny) San Francisco. The main frag...
›
Home
View web version
Powered by Blogger.